Paving the Way for Biomedical Innovation

The Frederick National Laboratory meets the nation’s most urgent biomedical research needs and serves as a national and global resource for the scientific community. 

New training series for rapid response clinical research available for free

A new virtual training series aims to educate and empower clinical researchers to perform rapid response clinical studies in...

New cancer data commons expands available clinical and translational data

A collaboration between development teams from the National Cancer Institute and the Frederick National Laboratory for Cancer...

Infectious diseases scientific meeting highlights findings of NIAID mpox vaccine study supported by FNL

Results of a Phase 2 clinical trial in adolescents that showed a vaccine to prevent mpox was safe and generated an antibody...

The widely used model organism zebrafish may help shed light on blood-brain barrier

Zebrafish were the original pet-store Glofish, popular for tropical aquaria despite their Himalayan origins. In science, they...

RAS drug discovery at Frederick National Laboratory reaches lung cancer patients in a clinical trial

An investigational treatment co-discovered by RAS Initiative scientists at the Frederick National Laboratory (FNL) is now...

Biotech Connector illuminates structural biology research

Structural biology has been in existence since 1912, when German physicist Max Von Laue first directed X-rays at crystallized...

Symposium: Technology Showcase team blends new and old approaches for 2024 event

After eight years, the annual Technology Showcase isn’t showing any signs of slowing. In fact, according to members of the...
What is this?

The Nanotechnology Characterization Laboratory characterizes nanomedicine formulations, as seen in this assay, for physiochemical traits and immunology, pharmacology and toxicology properties.

Information
Initiative

RAS Initiative

The RAS Initiative mobilizes the cancer research community to develop ways to treat cancers driven by the mutant RAS gene in an open model of collaboration among government, academic, and industry researchers.
220,000
People per year in the U.S. are diagnosed with cancers caused by KRAS mutations.
What is this? Surface representation of the structure of an oncogenic mutant of KRAS in complex with RAS-binding domains of RAF1 Kinase. The GMPPNP bound to oncogenic KRAS mutant is shown in ball-and-stick representation.
Information

SeroNet

The Serological Sciences Network, or SeroNet, is a collaboration to enhance understanding of the immune response to the novel coronavirus, SARS-CoV-2. SeroNet supports research projects in basic and applied serological research related to COVID-19 and increasing the nation’s serological testing capacity.
170
U.S. SARS-CoV-2 Serology Standard requests from industry, government and academic laboratories worldwide.

Our Passion is Infectious

Shape Your Career

Work with the best of the best biomedical researchers and investigators. Be a part of groundbreaking solutions that benefit public health throughout the world. And, enjoy some of the best benefits in the region. We are looking for smart, passionate problem solvers for benchwork, data science, manufacturing, and more.